Related Experiment Video
Updated: May 25, 2026
10:58
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Epithelial ovarian cancer
Joseph S Ng1, Jeffrey J H Low, A Ilancheran
1Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, National University Hospital, NUHS Tower Block, Singapore, Singapore. drjoeng@nus.edu.sg
Best Practice & Research. Clinical Obstetrics & Gynaecology
|January 28, 2012
Summary
Fertility-sparing surgery is a viable option for young women with early-stage epithelial ovarian cancer, preserving reproductive potential without compromising survival outcomes. Adjuvant chemotherapy is recommended and does not increase risks for future pregnancies.
Area of Science:
- Gynecologic Oncology
- Reproductive Endocrinology
- Surgical Oncology
Background:
- Epithelial ovarian cancer (EOC) in women aged 40 or younger presents unique management challenges, necessitating a balance between effective cancer treatment and reproductive potential preservation.
- The incidence of EOC in this demographic ranges from 3-17%.
Purpose of the Study:
- To evaluate the efficacy and safety of fertility-sparing surgical approaches in young women diagnosed with early-stage epithelial ovarian cancer.
- To assess the impact of adjuvant therapies on oncologic outcomes and subsequent pregnancy health.
Main Methods:
- Review of management strategies for premenopausal women with EOC.
- Analysis of outcomes associated with fertility-sparing surgery, including staging and cytoreductive procedures.
- Evaluation of adjuvant chemotherapy, targeted therapy, and ovarian cryopreservation in this patient population.
Main Results:
- Fertility-sparing surgery, involving complete staging and cytoreduction while retaining reproductive organs, demonstrates equivalent oncologic and clinical outcomes compared to standard treatments.
- Adjuvant platinum-taxane chemotherapy, when indicated, improves cancer and survival outcomes.
- Adjuvant treatment does not appear to elevate the risk of congenital anomalies in subsequent pregnancies.
Conclusions:
- Fertility-sparing surgery is a recommended approach for select young women with early-stage EOC, effectively balancing cancer treatment with reproductive preservation.
- Platinum-taxane adjuvant chemotherapy is advised for indicated cases, enhancing patient outcomes.
- Ovarian cryopreservation and targeted therapies are considered experimental and not part of the current standard of care.
Related Concept Videos
02:07Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
01:27Ovarian Cycle
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...